Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 12/20 | 0.61 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 3/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2310082 | 1.00 | DRD4 (0.61) | DRD4DRD1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2769599 | 1.00 | DRD4 (0.61) | DRD4DRD1CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL13277453 | 0.98 | DRD4 (0.60) | DRD4DRD1CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL13277454 | 0.98 | DRD4 (0.60) | DRD4DRD1CYP1A2CYP3A4CYP2D6 | |
| Ammonia Solution, Strong SCHEMBL3510860 | 0.98 | DRD4 (0.60) | DRD4DRD1CYP1A2CYP3A4CYP2D6 | |
| Dimethylamine SCHEMBL7924053 | 0.95 | DRD4 (0.57) | DRD4DRD1CYP1A2CYP3A4CYP2D6 | |
| Dimethylamine SCHEMBL10556770 | 0.94 | DRD4 (0.56) | DRD4DRD1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL18785465 | 0.87 | MC4R (0.50) | DRD4DRD1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12375 | 0.85 | ALDH1A1 (0.49) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16007596 | 0.84 | DRD4 (0.58) | DRD4DRD1CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2015-10-15 | — | — | US | claimed |
| EP-2350090-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2015-06-03 | — | — | EP | claimed |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-06-27 | — | — | US | claimed |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-11-22 | — | — | US | claimed |
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | claimed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | claimed |
| EP-2470508-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2012-07-04 | — | — | EP | claimed |
| EP-2350090-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | claimed |
| WO-2011025541-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | WO | claimed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | claimed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | claimed |
| US-4748175-A | Pyrimido[5,4-B][1,4]oxazine derivatives and pharmaceutical compositions containing them | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT (HU) | 1988-05-31 | — | — | US | claimed |
| US-11771695-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220241274-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | disclosed |
| US-5191079-A | Chemical intermediates for bactericides | KANEBO, LTD. (JP) | 1993-03-02 | — | — | US | disclosed |
| US-5166203-A | QUINOLINECARBOXYLIC ACID DERIVATIVES, ANTIBACTERIAL AGENT CONTAINING THE SAME | KANEBO, LTD. (JP) | 1992-11-24 | — | — | US | disclosed |
| CN-1059339-A | New quinoline carboxylic acid derivative, the antiseptic-germicide that contains them and their method for making | KANEBO LTD (JP) | 1992-03-11 | — | — | CN | disclosed |
| EP-0472826-A2 | Novel quinolinecarboxylic acid derivatives, use thereof, antibacterial agent containing the same, process for preparing said compounds and intermediate compound | KANEBO LTD. (JP) | 1992-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | DRD4 2045/4885DRD1 1465/4885CYP1A2 2151/4885 |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | DRD4 925/4885DRD1 711/4885CYP1A2 846/4885 |
| US-11746091-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | DRD4 2045/4885DRD1 1465/4885CYP1A2 2151/4885 |
| US-20220241274-A1 | CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | DRD4 1596/4885DRD1 1041/4885CYP1A2 684/4885 |
| US-11771695-B2 | Cannabinoid receptor modulators | CNR2, CNR1, OPRL1 | DRD4 1596/4885DRD1 1041/4885CYP1A2 684/4885 |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | TRPV3, TRPC3, TRPV1 | DRD4 986/4885DRD1 793/4885CYP1A2 920/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | DRD4 925/4885DRD1 711/4885CYP1A2 846/4885 |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | DRD4 2045/4885DRD1 1465/4885CYP1A2 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.